- Home
- KLTO vs IMRN Comparison
KLTO vs IMRN Comparison
Compare KLTO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- IMRN
- Stock Information
- Founded
- KLTO 2019
- IMRN 1994
- Country
- KLTO United States
- IMRN Australia
- Employees
- KLTO N/A
- IMRN N/A
- Industry
- KLTO
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- IMRN Health Care
- Exchange
- KLTO NYSE
- IMRN Nasdaq
- Market Cap
- KLTO 9.8M
- IMRN 10.1M
- IPO Year
- KLTO N/A
- IMRN N/A
- Fundamental
- Price
- KLTO $0.18
- IMRN $1.80
- Analyst Decision
- KLTO
- IMRN Strong Buy
- Analyst Count
- KLTO 0
- IMRN 1
- Target Price
- KLTO N/A
- IMRN $5.00
- AVG Volume (30 Days)
- KLTO 78.7K
- IMRN 13.7K
- Earning Date
- KLTO 05-15-2025
- IMRN 04-15-2025
- Dividend Yield
- KLTO N/A
- IMRN N/A
- EPS Growth
- KLTO N/A
- IMRN N/A
- EPS
- KLTO N/A
- IMRN N/A
- Revenue
- KLTO N/A
- IMRN $4,048,286.00
- Revenue This Year
- KLTO N/A
- IMRN N/A
- Revenue Next Year
- KLTO N/A
- IMRN N/A
- P/E Ratio
- KLTO N/A
- IMRN N/A
- Revenue Growth
- KLTO N/A
- IMRN 82.90
- 52 Week Low
- KLTO $0.20
- IMRN $1.70
- 52 Week High
- KLTO $13.10
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- IMRN 55.96
- Support Level
- KLTO N/A
- IMRN $1.75
- Resistance Level
- KLTO N/A
- IMRN $2.09
- Average True Range (ATR)
- KLTO 0.00
- IMRN 0.13
- MACD
- KLTO 0.00
- IMRN 0.01
- Stochastic Oscillator
- KLTO 0.00
- IMRN 51.28
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.